Rapamycin in children after liver transplantation

Area of Science:

• Immunology
• Nephrology
• Hepatology

Background:

• Limited data exists on sirolimus (SRL) use in pediatric liver transplantation (LTx).
• Tacrolimus is a common immunosuppressant post-LTx, but renal impairment and chronic rejection are significant concerns.

Purpose of the Study:

• To evaluate the safety and efficacy of sirolimus in pediatric liver transplant recipients.
• To assess SRL's impact on renal function, liver function, and adverse events in this population.

Main Methods:

• Retrospective analysis of 9 pediatric liver transplant patients treated with SRL over 2 years.
• SRL was administered for chronic rejection or renal dysfunction, with specific target trough levels for SRL and tacrolimus.
• Patient outcomes were monitored for liver function, renal function (GFR), and side effects.

Main Results:

• All 9 patients survived, with 3 showing resolution of chronic rejection and normalized liver biochemistry.
• Significant renal function improvement was observed in all patients, including improved GFR.
• Elevated serum cholesterol was a common side effect; SRL was discontinued in 3 patients due to adverse events.

Conclusions:

• Sirolimus is a viable option for pediatric liver transplant patients, particularly those with chronic rejection or renal impairment.
• SRL, alone or with reduced tacrolimus, can improve renal function post-transplantation.
• Careful monitoring for side effects, such as hypercholesterolemia and opportunistic infections, is recommended.